Oncology Today with Dr Neil Love

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies

CAR T-cell therapy has fundamentally shifted the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, effectively replacing autologous stem cell transplant as the standard of care for second-line therapy. While CAR T-cell constructs provide curative potential, bispecific antibodies—such as glofita...

Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Small cell lung cancer management has entered a transformative era, shifting from traditional chemotherapy to advanced chemo-immunotherapy and targeted strategies. First-line extensive-stage treatment now centers on chemo-immunotherapy, with maintenance options like lurbinectedin demonstrating significant progression-f...

Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Chronic Lymphocytic Leukemia (CLL) management has transitioned from traditional chemoimmunotherapy to targeted therapies, specifically BTK and BCL2 inhibitors. Continuous BTK inhibition remains a standard, though newer, more selective agents like acalabrutinib and zanabrutinib offer improved cardiovascular and safety p...

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR

Targeted therapies for non-small cell lung cancer (NSCLC) have evolved significantly, shifting from early-generation inhibitors to highly potent, selective agents with superior progression-free survival (PFS). The discussion highlights the distinction between kinase mutations and gene fusions, noting that fusions often...

For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress

TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3

Management of HER2-altered non-small cell lung cancer (NSCLC) is evolving rapidly with the integration of HER2-directed antibody-drug conjugates like trastuzumab deruxtecan (T-DXd) and novel tyrosine kinase inhibitors (TKIs) such as zongertinib and sevabertinib. Clinical data from the DESTINY-Lung02 trial demonstrate t...

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

HER2-altered non-small cell lung cancer management is undergoing a significant shift with the emergence of targeted tyrosine kinase inhibitors. Zongertinib demonstrates robust efficacy, achieving a 71% response rate in previously treated patients and 77% in the frontline setting, with a favorable safety profile charact...

For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Neoadjuvant PD-1 blockade has transformed the management of MSI-high/dMMR locally advanced rectal cancer, yielding high clinical complete response rates and offering a potential alternative to traditional chemoradiation and surgery. In colon cancer, molecular residual disease (MRD) testing through ctDNA serves as a cri...

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2

Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

The management of hormone receptor-positive, HER2-low metastatic breast cancer increasingly relies on targeting endocrine resistance through oral selective estrogen receptor degraders (SERDs) and PI3K pathway inhibitors. Clinical strategies now prioritize identifying ESR1 mutations via circulating tumor DNA to guide tr...

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress